Anne Borgman
Chief Tech/Sci/R&D Officer chez SUTRO BIOPHARMA, INC.
Fortune : 137 713 $ au 31/03/2024
Profil
Anne E Borgman is currently a Director at Curis, Inc. She also holds current positions as an Independent Director at NextCure, Inc., Director at NiKang Therapeutics, Inc., and Chief Medical Officer at Sutro Biopharma, Inc. In the past, she worked as Head-Global Project at Abbott Laboratories, Vice President-Clinical Research & Development at Exelixis, Inc., and Vice President & Head-Global Therapeutic Area at Jazz Pharmaceuticals Plc.
She also served as Clinical Associate-Pediatrics at The University of Chicago and held positions as Chief Medical Officer & Vice President at both Humanigen, Inc. and Talon Therapeutics, Inc. Additionally, she was an Associate Chief Medical Officer at Kalobios Pharmaceuticals, Inc. Dr. Borgman received her undergraduate degree from the University of Illinois and her doctorate from Stritch School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SUTRO BIOPHARMA, INC.
0,04% | 05/03/2024 | 24 374 ( 0,04% ) | 137 713 $ | 31/03/2024 |
NEXTCURE, INC.
-.--% | 22/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Anne Borgman
| Sociétés | Poste | Début |
|---|---|---|
| NEXTCURE, INC. | Director/Board Member | 01/10/2021 |
| CURIS, INC. | Director/Board Member | - |
| SUTRO BIOPHARMA, INC. | Chief Tech/Sci/R&D Officer | 28/02/2023 |
NiKang Therapeutics, Inc.
 NiKang Therapeutics, Inc. BiotechnologyHealth Technology NiKang Therapeutics, Inc. operates as biotechnology company. It focuses on developing novel small molecule oncology drug discovery. The company was founded by Zhenhai Gao and is headquartered in Wilmington, DE. | Director/Board Member | 18/01/2023 |
Anciens postes connus de Anne Borgman
| Sociétés | Poste | Fin |
|---|---|---|
| JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | 01/03/2022 |
| EXELIXIS, INC. | Corporate Officer/Principal | 01/07/2019 |
| The University of Chicago | Corporate Officer/Principal | 01/01/2010 |
| ABBOTT LABORATORIES | Corporate Officer/Principal | 01/11/2007 |
| Kalobios Pharmaceuticals, Inc. | Corporate Officer/Principal | - |
Formation de Anne Borgman
| University of Illinois | Undergraduate Degree |
| Stritch School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 7 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| EXELIXIS, INC. | Health Technology |
| CURIS, INC. | Health Technology |
| HUMANIGEN, INC. | Health Technology |
| SUTRO BIOPHARMA, INC. | Health Technology |
| JAZZ PHARMACEUTICALS PLC | Health Technology |
| NEXTCURE, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Talon Therapeutics, Inc.
 Talon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talon Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the developing and commercializing new and differentiated cancer therapies. The firm is developing the Marqibo for the treatment of acute lymphoblastic leukemia and other blood cancers including lymphoma. Its Menadione topical lotion is a compound which is developed for the prevention and treatment of skin toxicity associated with epidermal growth factor receptor inhibitors. The company was founded by Mark J. Ahn in 2002 and is headquartered in San Mateo, CA. | Health Technology |
NiKang Therapeutics, Inc.
NiKang Therapeutics, Inc. BiotechnologyHealth Technology NiKang Therapeutics, Inc. operates as biotechnology company. It focuses on developing novel small molecule oncology drug discovery. The company was founded by Zhenhai Gao and is headquartered in Wilmington, DE. | Health Technology |
| Kalobios Pharmaceuticals, Inc. |
